Richard Bryant, MD
Ophthalmology · Dothan, ALNPI 1578586327
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $105 and has fallen 53.2% since, to $49 in 2025. That places this record below the midpoint for ophthalmology clinicians in AL, where the typical reported total is $1,678.
Across 20 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$86
- AbbVie$77
- Kala Pharmaceuticals, Inc.$40
- Glaukos Corporation$40
- Novartis$34
- Otsuka America Pharmaceutical, Inc.$28
- plus $89 from 5 others
What the payments were for
- Food & beverage$37595%
- Gifts$195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 4 | $86 |
| AbbVie(2 entities) | 4 | $77 |
| Kala Pharmaceuticals, Inc. | 2 | $40 |
| Glaukos Corporation | 1 | $40 |
| Novartis | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Amgen | 2 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Alcon | 1 | $13 |
How this compares
$395 in reported general payments places this provider in the 20th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 11 | $15,584 |
| ErythromycinErythromycin Base | 147 | $1,661 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 292 | $1,007 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 77 | $1,002 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 56 | $503 |
| Cephalexin | 56 | $337 |
| Methylprednisolone | 23 | $208 |
| Azithromycin | 36 | $140 |
| Doxycycline Hyclate | 13 | $94 |
| Tramadol Hcl | 38 | $63 |
| Promethazine Hcl | 13 | $27 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Dothan
- Sebastian HeersinkDothan$33K
- Harsha SenDothan$11K
- Kirk SturridgeDothan$11K
- Aaron McKinleyDothan$8K
- Warren ThompsonDothan$6K
- Marius HeersinkDothan$3K
- Jorge ArangoDothan$3K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.